

**Akcea Therapeutics, Inc.**  
**Charter of the Nominating, Governance and Review Committee**  
(approved May 2, 2017; revised September 17, 2019)

The Nominating, Governance and Review Committee of the Board of Directors of Akcea Therapeutics, Inc. shall consist of at least two directors and, so long as Ionis Pharmaceuticals, Inc. holds more than 50% of the voting power for the election of directors of Akcea, a majority of the members of the Nominating, Governance and Review Committee will not be employees or directors of Ionis.

Each member of the Nominating, Governance and Review Committee must be independent of the Company, *provided, that*, as long as Ionis holds more than 50% of the voting power for election of directors of Akcea, officers or directors of Ionis may serve on the Nominating, Governance and Review Committee. Members of the committee will be considered independent as long as they meet the independence requirements of the applicable Nasdaq rules. The Nominating, Governance and Review Committee shall be charged with the following functions:

1. Interview, evaluate, nominate and recommend individuals for membership on Akcea's Board of Directors. As part of this process the Nominating, Governance and Review Committee will consider nominees recommended by Akcea's stockholders.
2. On an annual basis, review the performance of the Board and its committees, including evaluating the Boards' ability to function as a group and the integrity and competency of the individual Board members.
3. Annually review and assess the adequacy of Akcea's corporate governance guidelines and recommend any proposed changes to the Board for approval.
4. In the discharge of its functions, duly consider interests that are unique to Akcea's minority stockholders.
5. To perform such other functions and have such other powers as may be necessary or convenient in the efficient discharge of the foregoing.